Bone Biologics Corp

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Balance Sheets

Condensed Consolidated Balance Sheets

	September 30, 2024	December 31, 2023
(unaudited)
Assets
Current Assets
Cash	$3,566,426	$3,026,569
Advances on research and development contract services	385,742	328,844
Prepaid insurance	95,220	372,350
Prepaid expenses	18,430	10,000
Total current assets	4,065,818	3,737,763
Total assets	$4,065,818	$3,737,763
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued expenses	$190,057	$360,662
Research and development contract liabilities	65,716	-
Accrued legal settlement	-	414,989
Warrant liability	17,629	55,751
Total current liabilities	273,402	831,402
Total liabilities	273,402	831,402
Commitments and Contingencies	-
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at September 30, 2024 and December 31, 2023	-	-
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 2,096,740 and 534,238 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	2,096	534
Additional paid-in capital	87,289,983	83,814,785
Accumulated deficit	(83,499,663)	(80,908,958)
Total stockholders’ equity	3,792,416	2,906,361
Total liabilities and stockholders’ equity	$4,065,818	$3,737,763

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.